丙型肝炎病毒载量与基因型和抗病毒疗效的关系研究

doi:10.3969/j.issn.1672-5069.2011.05.008

摘要/Abstract

摘要： 目的探讨丙型肝炎患者血清HCV RNA载量与基因型的关系及其对抗病毒治疗疗效的影响。方法 113例慢性丙型肝炎患者接受聚乙二醇干扰素联合利巴韦林抗病毒治疗。采用实时荧光定量PCR法检测血清HCV RNA载量，应用CE1区测序遗传树比对分析法检测HCV基因型。结果 113例患者分别感染1b、2a、3a、3b和6a共5种基因亚型，其HCV RNA载量（lgcopies/ml）分别为6.6973±1.19245、6.0824±1.68603、6.8393±1.03400、6.5533±1.29577和7.1503±1.16115，经单因素方差分析无明显统计学差异（P=0.166）；治疗前高血清HCV RNA载量者（≥107copies/ml）与低HCV RNA载量者（＜107copies /ml）完成治疗后获得SVR的比例，无论在所有患者（76.4%对75.9%，P=0.950），还是在HCV1型（66.7%对60.0%，P=0.641）或非1型感染者（82.4%对87.9%，P=0.526）中均无统计学差异。结论治疗前血清HCV RNA载量与HCV基因型无关，血清HCV RNA载量对聚乙二醇干扰素联合利巴韦林抗病毒的疗效无明显影响。

关键词: 慢性丙型肝炎, HCV RNA, 基因型, 聚乙二醇干扰素

Abstract: Objective To investigate whether the level of viremia differs in accordance with genotypes and responses to pegylated interferon and ribavirin treatment in patients with chronic hepatitis C. Methods 113 patients with chronic hepatitis C were treated with pegylated interferon and ribavirin. The level of serum HCV RNA was measured with real-time quantitative reverse-transcription polymerase chain reaction and HCV genotypes were determined by core-envelope1 region nucleotide sequencing followed by phylogenic analysis. Results There were five different subtypes of HCV in 113 patients，including 1b（40.7%），2a（13.3%），3a（9.7%），3b（17.7%）and 6a（18.6%）. The serum HCV RNA（lgcopies/ml）of them were 6.6973±1.19245，6.0824±1.68603，6.8393±1.03400，6.5533±1.29577 and 7.1503±1.16115，respectively；There was no significant relationship between serum HCV RNA and genotypes（F=1.652，P=0.166）；The rate of SVR in patients with higher serum HCV RNA（≥107copies/ml） was similar to that seen in patients with lower serum HCV RNA（＜107copies/ml），whether in the total patients（76.4%vs.75.9%，P=0.950），or in the HCV1b infections（66.7% vs.60.0%，P=0.641）or in the non-HCV1 infected patients（82.4%vs.87.9%，P=0.526）. Conclusions The levels of HCV RNA differ neither in different subtypes of HCV infection nor in different responses to pegylated interferon and ribavirin therapy.

Key words: Hepatitis C, Quantitative PCR, Genotypes, Pegylated interferon

周友乾,尹凤鸣,冯经华. 丙型肝炎病毒载量与基因型和抗病毒疗效的关系研究[J]. 实用肝脏病杂志, 2011, 14(5): 340-342.

ZHOU Youqian，YIN Fengming，FENG Jinghua. The relationship of HCV RNA levels to HCV genotypes as well as to responses to pegylated interferon and ribavirin therapy in patients with chronic hepatitis C[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2011, 14(5): 340-342.

参考文献

[1] NGUYEN-KHAC E，CAPRON D，ASTELAIN S，et al. Personalized therapy for chronic viral hepatitis C in the naive patient:How can we optimize treatment duration as a function of viral genotype[J]. Eur J Intern Med，2007，18（7）:510-515.
[2] CHAKRAVARTI A，DOGRA G，VERMA V，et al. Distribution pattern of HCV genotypes & its association with viral load[J].Indian J Med Res，2011，133（3）:326-331.
[3] FERNáNDEZ I，CASTELLANO G，DOMINGO MJ，et al.Influence of viral genotype and level of viremia on the severity of liver injury and the response to interferon therapy in Spanish patients with chronic C infection[J]. Scand J Gastroenterol，1997，32（1）:70-76.
[4] Kü?K?ZTAＳ MF，OZGüNES N，YAZICI S. Investigation of the relationship between hepatitis c virus（HCV）genotypes with HCV-RNA and alanine aminotransferase levels in chronic hepatitis C patients[J]. Mikrobiyol Bul，2010，44（1）:111-115.
[5] YU ML，CHUANG WL. Treatment of chronic hepatitis C in Asia:when East meets West[J]. J Gastroenterol Hepatol，2009，24（3）:336-345.
[6] 张帆，王小红，王宇明，等. 重庆地区HCV基因亚型的分布状态[J]. 第四军医大学学报，2005，26（14）:1253-1256.
[7] JENS B，PHILIP M，RAYMOND T，et al. Challenge pools of hepatitis C virus genotypes 1-6 prototype strains:Replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models[J]. J Infect Dis，2010，201（9）:1381-1389.
[8] ELKADY A，TANAKA Y，KURBANOV F，et al. Performance of two real-time RT-PCR assays for quantitation of hepatitis C virus RNA:evaluation on HCV genotypes 1-4[J]. J Med Virol，2010，82（11）:1878-1888.
[9] SIMMONDS P，BUKH J，COMBET C，et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes[J]. Hepatology，2005，42（4）:962-973.
[10] CANTALOUBE JF，LAPERCHE S，GALLIAN P，et al. Analysis of the 5' noncoding region versus the NS5b region in genotyping hepatitis C virus isolates from blood donors in France[J]. J Clin Microbiol，2006，44（6）:2051-2056.
[11] SCHINKEL J，KROES AC，WAGTMANS MJ，et al. Monitoring response during a randomised controlled trial of escalating interferon dose for chronic hepatitis C infection:predictive value of quantitative and qualitative HCV RNA assays[J]. J Clin Virol，2001，22（1）:61-71.
[12] TAKENOKUCHI M，YASUDA C，NAKAMACHI Y，et al. Comparative evaluation of serum HCV RNA by Roche Monitor Assay. Versions 1.0 and 2.0；as a predictive marker of subsequent response to IFN therapy[J]. Rinsho Byori，2002，50（4）:392-397.
[13] LEE SD，YU ML，CHENG PN，et al. Comparison of a 6-month course peginterferon a-2b plus ribavirin and interferon a-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan[J]. J Viral Hepatitis，2005，12，283-291.
[14] DAVID LT，CHLOE LT，MAUREEN PM，et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus[J]. Nature，2010，461:798-802.
[15] 周友乾，王小红，范熠，等. 抗丙型肝炎病毒治疗中的病毒学应答对持续应答的预测价值[J]. 中华肝脏病杂志，2009，17（12）:944-946.